Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination

The humoral immunity after SARS-CoV-2 infection or vaccination was examined. Convalescent sera after infection with variants of concern (VOCs: B.1.1.7, n = 10; B.1.351, n = 1) and sera from 100 vaccinees (Pfizer/BioNTech, BNT162b2, n = 33; Moderna, mRNA-1273, n = 11; AstraZeneca, ChAdOx1 nCoV-19/AZD...

Descripción completa

Detalles Bibliográficos
Autores principales: Neumann, Franziska, Rose, Ruben, Römpke, Janine, Grobe, Olaf, Lorentz, Thomas, Fickenscher, Helmut, Krumbholz, Andi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310178/
https://www.ncbi.nlm.nih.gov/pubmed/34202276
http://dx.doi.org/10.3390/vaccines9070700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310178/
https://www.ncbi.nlm.nih.gov/pubmed/34202276
http://dx.doi.org/10.3390/vaccines9070700

Ejemplares similares